M&A Deal Summary

LabGenomics Acquires IMD

On October 25, 2024, LabGenomics acquired life science company IMD

Acquisition Highlights
  • This is LabGenomics’ 2nd transaction in the Life Science sector.
  • This is LabGenomics’ 2nd transaction in the United States.
  • This is LabGenomics’ 1st transaction in California.

M&A Deal Summary
Date 2024-10-25
Target IMD
Sector Life Science
Buyer(s) LabGenomics
Deal Type Add-on Acquisition

Target

IMD

Berkeley, California, United States
IMD specializes in molecular diagnostics and provides advanced technology and infrastructure to support community-based pathology and oncology practices, particularly in the field of cancer management. IMD is based in Berkeley, California.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

LabGenomics

Seongnam-si, South Korea
Category Company
Founded 2002
Sector Life Science
Revenue 73.1B KRW (2023)
DESCRIPTION

LabGenomics is a healthcare company specializing in molecular diagnostics. LabGenomics offers several cancer tests including ‘BRCA1/BRCA2,’ ‘comprehensive genetic cancer panel,’ and ‘OTD-Solid’ test. LabGenomics was formed in 2002 and is based in Seongnam-si, South Korea.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (California) 1 of 1
Country (United States) 2 of 2
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-05 Qdx Pathology Services

Edison, New Jersey, United States

Qdx Pathology Services provides personalized laboratory services, as well as a full range of ancillary support and practice management solutions. Qdx Pathology Services is based in Edison, New Jersey.

Buy -
Mergr

Product

Company

Legal